114 related articles for article (PubMed ID: 7581113)
1. Cytokine-mediated immunotherapy with or without donor leukocytes for poor-risk acute myeloid leukemia relapsing after allogeneic bone marrow transplantation.
Mehta J; Powles R; Singhal S; Tait D; Swansbury J; Treleaven J
Bone Marrow Transplant; 1995 Jul; 16(1):133-7. PubMed ID: 7581113
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes.
Slavin S; Naparstek E; Nagler A; Ackerstein A; Kapelushnik J; Or R
Exp Hematol; 1995 Dec; 23(14):1553-62. PubMed ID: 8542946
[TBL] [Abstract][Full Text] [Related]
3. Allogeneic peripheral blood progenitor cells for treatment of relapse after bone marrow transplantation.
Glass B; Majolino I; Dreger P; Scimè R; Santoro A; Vasta S; Suttorp M; Haferlach T; Schmitz N
Bone Marrow Transplant; 1997 Oct; 20(7):533-41. PubMed ID: 9337054
[TBL] [Abstract][Full Text] [Related]
4. Effect of induced GVHD in leukemia patients relapsing after allogeneic bone marrow transplantation: single-center experience of 33 adult patients.
Min CK; Eom KS; Lee S; Kim DW; Lee JW; Min WS; Kim CC
Bone Marrow Transplant; 2001 May; 27(9):999-1005. PubMed ID: 11436112
[TBL] [Abstract][Full Text] [Related]
5. [Treatment of leukemia relapsed after allogenic bone marrow transplantation with donor lymphocyte infusion: report of 11 cases].
Sanz Rodríguez C; Steegmann JL; Granda A; de la Cámara R; Figuera A; Arranz R; Gómez-García de Soria V; Alegre A; Fernández-Rañada JM
Sangre (Barc); 1999 Dec; 44(6):456-63. PubMed ID: 10822760
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic bone marrow transplantation for children with acute leukemia: long-term follow-up of patients prepared with high-dose cytosine arabinoside and fractionated total body irradiation.
Gordon BG; Warkentin PI; Strandjord SE; Abromowitch M; Bayever E; Harper JL; Coccia PF
Bone Marrow Transplant; 1997 Jul; 20(1):5-10. PubMed ID: 9232249
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy with donor leukocyte infusions for patients with relapsed acute myeloid leukemia following partially mismatched related donor bone marrow transplantation.
Pati AR; Godder K; Lamb L; Gee A; Henslee-Downey PJ
Bone Marrow Transplant; 1995 Jun; 15(6):979-81. PubMed ID: 7581101
[TBL] [Abstract][Full Text] [Related]
8. Adoptive immunotherapy with donor mononuclear cell infusions to treat relapse of acute leukemia or myelodysplasia after allogeneic bone marrow transplantation.
Porter DL; Roth MS; Lee SJ; McGarigle C; Ferrara JL; Antin JH
Bone Marrow Transplant; 1996 Nov; 18(5):975-80. PubMed ID: 8932854
[TBL] [Abstract][Full Text] [Related]
9. Long-term follow-up of patients undergoing allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission after cyclophosphamide-total body irradiation and cyclosporine.
Mehta J; Powles R; Treleaven J; Horton C; Tait D; Meller S; Pinkerton CR; Middleton G; Eisen T; Singhal S
Bone Marrow Transplant; 1996 Oct; 18(4):741-6. PubMed ID: 8899189
[TBL] [Abstract][Full Text] [Related]
10. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH
Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic and autologous bone marrow transplantation after consolidation therapy in high-risk acute myeloid leukemia in children. Towards a risk-oriented therapy.
Ortega JJ; Díaz de Heredia C; Olivé T; Bastida P; Llort A; Armadans L; Torrabadella M; Massuet L
Haematologica; 2003 Mar; 88(3):290-9. PubMed ID: 12651268
[TBL] [Abstract][Full Text] [Related]
12. Donor leucocyte infusions after chemotherapy for patients relapsing with acute leukaemia following allogeneic BMT.
Szer J; Grigg AP; Phillips GL; Sheridan WP
Bone Marrow Transplant; 1993 Feb; 11(2):109-11. PubMed ID: 8435660
[TBL] [Abstract][Full Text] [Related]
13. Donor leukocyte infusions for treatment of relapsed acute myeloid leukemia after allogeneic bone marrow transplantation.
Forés R; Díez-Martin JL; Briz M; Cabrera JR; Sanjuán I; Regidor C; Garcia-Talavera J; Fernandez MN
Bone Marrow Transplant; 1996 Mar; 17(3):439-41. PubMed ID: 8704703
[TBL] [Abstract][Full Text] [Related]
14. Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells.
Verdonck LF; Petersen EJ; Lokhorst HM; Nieuwenhuis HK; Dekker AW; Tilanus MG; de Weger RA
Bone Marrow Transplant; 1998 Dec; 22(11):1057-63. PubMed ID: 9877267
[TBL] [Abstract][Full Text] [Related]
15. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
16. Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: lower incidence of acute graft-versus-host disease and improved outcome.
Shiobara S; Nakao S; Ueda M; Yamazaki H; Takahashi S; Asano S; Yabe H; Kato S; Imoto S; Maruta A; Yoshida T; Gondo H; Morishima Y; Kodera Y
Bone Marrow Transplant; 2000 Oct; 26(7):769-74. PubMed ID: 11042659
[TBL] [Abstract][Full Text] [Related]
17. Induction of a graft-versus-leukemia reaction by cyclosporin A withdrawal as immunotherapy for leukemia relapsing after allogeneic bone marrow transplantation.
Elmaagacli AH; Beelen DW; Trenn G; Schmidt O; Nahler M; Schaefer UW
Bone Marrow Transplant; 1999 Apr; 23(8):771-7. PubMed ID: 10231138
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.
Naparstek E; Nagler A; Or R; Kapelushnik J; Slavin S
Clin Transpl; 1996; ():281-90. PubMed ID: 9286578
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic bone marrow transplantation for leukemia with marrow grafts treated by counterflow centrifugation.
De Witte T; Schattenberg A; Preijers F; Raymakers R; Muus P; Wessels J
Bone Marrow Transplant; 1993; 12 Suppl 3():S2-6. PubMed ID: 8124252
[TBL] [Abstract][Full Text] [Related]
20. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F
Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]